Using genetically engineered mouse models, we determined that in HER2/Neu-driven mammary tumors Rac1b is expressed by a substantial subset of BCSCs, which require Rac1b function for their maintenance/activity, and the loss-of Rac1b function sensitizes them to the chemotherapeutic effect of doxorubicin treatment. This evidence concerns the gene ERBB2 and breast cancer.